Raphael Pharm Financials
This page shows Raphael Pharm (RAPH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Raphael Pharm passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Raphael Pharm generates $0.35 in operating cash flow (-$532K OCF vs -$1.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Raphael Pharm reported -$1.5M in net income in fiscal year 2024. This represents a decrease of 13.0% from the prior year.
Raphael Pharm earned $0.08 per diluted share (EPS) in fiscal year 2024. This represents an increase of 0.0% from the prior year.
Raphael Pharm held $19K in cash against $0 in long-term debt as of fiscal year 2024.
Raphael Pharm had 19M shares outstanding in fiscal year 2024. This represents an increase of 1.1% from the prior year.
Raphael Pharm invested $776K in research and development in fiscal year 2024. This represents an increase of 36.4% from the prior year.
RAPH Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q2'23 | Q4'22 | Q3'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $73K-54.9% | $162K | N/A | $510K+74.1% | $293K | N/A | $332K+295.2% | $84K |
| SG&A Expenses | $178K+13.4% | $157K | N/A | $219K+73.8% | $126K | N/A | $1.1M+107.2% | $528K |
| Operating Income | -$251K+21.3% | -$319K | N/A | -$729K-74.0% | -$419K | N/A | -$1.4M-133.0% | -$612K |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$255K+21.8% | -$326K | N/A | -$725K-73.9% | -$417K | N/A | -$1.4M-130.1% | -$627K |
| EPS (Diluted) | $0.010.0% | $0.01 | N/A | $0.04+33.3% | $0.03 | N/A | $0.10+100.0% | $0.05 |
RAPH Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q2'23 | Q4'22 | Q3'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7K-74.1% | $27K-88.7% | $239K-40.7% | $403K+238.7% | $119K-64.3% | $333K+175.2% | $121K-38.3% | $196K |
| Current Assets | $5K-80.0% | $25K-89.5% | $237K-41.0% | $402K+240.7% | $118K-64.4% | $331K+178.2% | $119K-39.3% | $196K |
| Cash & Equivalents | $3K-84.2% | $19K-91.7% | $230K-23.1% | $299K+169.4% | $111K-61.5% | $288K+209.7% | $93K-31.1% | $135K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.3M+65.3% | $769K+2846.4% | -$28K-105.9% | $478K+165.6% | $180K-20.7% | $227K+24.0% | $183K+134.6% | $78K |
| Current Liabilities | $1.3M+65.3% | $769K+482.6% | $132K-72.4% | $478K+165.6% | $180K-20.7% | $227K+24.0% | $183K+134.6% | $78K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$1.3M-70.4% | -$742K-377.9% | $267K+456.0% | -$75K-23.0% | -$61K-157.5% | $106K+271.0% | -$62K-152.5% | $118K |
| Retained Earnings | -$9.9M-11.3% | -$8.9M-20.6% | -$7.4M+0.8% | -$7.4M-10.8% | -$6.7M-11.3% | -$6.0M-22.4% | -$4.9M-41.5% | -$3.5M |
RAPH Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q2'23 | Q4'22 | Q3'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$17K+72.6% | -$62K+29.5% | -$88K+82.4% | -$501K-133.0% | -$215K+22.4% | -$277K-82.2% | -$152K+38.7% | -$248K |
| Capital Expenditures | N/A | $1K | N/A | N/A | N/A | $0 | N/A | N/A |
| Free Cash Flow | N/A | -$173K | N/A | N/A | N/A | -$277K | N/A | N/A |
| Investing Cash Flow | N/A | -$1K | N/A | N/A | N/A | $0 | N/A | N/A |
| Financing Cash Flow | $0-100.0% | $41K+115.8% | $19K-97.2% | $689K+139.2% | $288K-39.0% | $472K+321.4% | $112K-62.9% | $302K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
RAPH Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q2'23 | Q4'22 | Q3'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -3642.9%-3003.6pp | -639.2% | N/A | -179.9%+170.5pp | -350.4% | N/A | -1192.6%-872.7pp | -319.9% |
| Current Ratio | 0.00-0.0 | 0.03-1.8 | 1.80+1.0 | 0.84+0.2 | 0.66-0.8 | 1.46+0.8 | 0.65-1.9 | 2.51 |
| Debt-to-Equity | -1.01+0.0 | -1.04-0.9 | -0.10+6.3 | -6.37-3.4 | -2.95-5.1 | 2.14+5.1 | -2.95-3.6 | 0.66 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$742K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
Is Raphael Pharm profitable?
No, Raphael Pharm (RAPH) reported a net income of -$1.5M in fiscal year 2024.
What is Raphael Pharm's earnings per share (EPS)?
Raphael Pharm (RAPH) reported diluted earnings per share of $0.08 for fiscal year 2024. This represents a 0.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Raphael Pharm's operating cash flow?
Raphael Pharm (RAPH) generated -$532K in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Raphael Pharm's total assets?
Raphael Pharm (RAPH) had $27K in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Raphael Pharm spend on research and development?
Raphael Pharm (RAPH) invested $776K in research and development during fiscal year 2024.
How many shares does Raphael Pharm have outstanding?
Raphael Pharm (RAPH) had 19M shares outstanding as of fiscal year 2024.
What is Raphael Pharm's current ratio?
Raphael Pharm (RAPH) had a current ratio of 0.03 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Raphael Pharm's debt-to-equity ratio?
Raphael Pharm (RAPH) had a debt-to-equity ratio of -1.04 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Raphael Pharm's return on assets (ROA)?
Raphael Pharm (RAPH) had a return on assets of -5625.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Raphael Pharm's cash runway?
Based on fiscal year 2024 data, Raphael Pharm (RAPH) had $19K in cash against an annual operating cash burn of $532K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Raphael Pharm's debt-to-equity ratio negative or unusual?
Raphael Pharm (RAPH) has negative shareholder equity of -$742K as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Raphael Pharm's Piotroski F-Score?
Raphael Pharm (RAPH) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Raphael Pharm's earnings high quality?
Raphael Pharm (RAPH) has an earnings quality ratio of 0.35x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.